Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Review fee comparisons across wide market index funds to find the lowest-cost option for retirement. Practical guidance to reduce recurring expenses.
28,610 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Ethereum eyes a critical support level as traders monitor a potential breakout. If the level holds, ethereum (eth) co...
A bold investing thesis centers on a single nuclear stock with big plans for small modular reactors and recycled fuel...
The VIX eased toward the mid-20s as equities edged higher and oil spiked on geopolitical tensions. Analysts say the m...
Bitcoin briefly pushed into the mid-$60,000s before pulling back, while a top analyst cautions that the bounce may no...
Bitcoin slips after the FOMC meeting, while XRP dips below $1.20. The move highlights renewed risk in the crypto mark...
Amazon's AI hardware strategy could extend far beyond cloud services. This article explains how Trainium and Inferent...
Ethereum broke above the $2,000 mark, signaling a potential rebound after a tough month. Analysts weigh ethereum pric...
Pricing power has long been Apple’s ace. Now the company faces a no-win pricing trap: raise prices risking demand, or...
Saudi Aramco’s CEO cautioned that oil markets may not normalize until 2027 as Strait of Hormuz disruptions persist, i...
Permanent Portfolio's Michael Cuggino argues Meta can invest heavily in AI without sacrificing profits. He emphasizes...
Verizon is shrinking its footprint and workforce as it pivots to a franchise-based retail model and tighter costs. Th...